{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021758","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.841197+00:00","generated_at":"2026-05-16T21:36:06.530754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus reports Q3 loss per share $2.98, cash $5.8M; pauses enrollment pending Decoy20 combo efficacy","bullets":["Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.","Completed Safety Lead-In cohort, dosing 6 participants with Decoy20 + tislelizumab; 3 stable disease, 2 remain on study.","Enrollment paused pending additional efficacy evaluation and assessment of next development options.","Raised $2.3M via ATM in September 2025; converted $5.7M promissory notes into stock/warrants in July."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021758","json":"https://secwatch.observer/filing/0001493152-25-021758.json","markdown":"https://secwatch.observer/filing/0001493152-25-021758.md","text":"https://secwatch.observer/filing/0001493152-25-021758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/0001493152-25-021758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:36:06.530754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}